Fact CheckerSign in

NCT07332156Completed

Lung Cancer Risk in Type 2 Diabetes With COPD: SGLT2 Inhibitors vs. Sulfonylureas

Lung Cancer Incidence in Patients With Type 2 Diabetes and COPD: A Real-World Retrospective Cohort Study Comparing SGLT2 Inhibitors and Sulfonylureas

Source: ClinicalTrials.gov · Last updated 14 Jan 2026

Brief summary (registry, in English)

The goal of this observational study is to learn if a specific diabetes medicine can lower the risk of lung cancer in people with type 2 diabetes and chronic obstructive pulmonary disease (COPD). The main question it aims to answer is: \- Does taking medicines called SGLT2 inhibitors lower the chance of getting lung cancer compared to medicines called sulfonylureas? Researchers will compare the medical records of people taking SGLT2 inhibitors to those taking sulfonylureas to see if the SGLT2 group has fewer cases of lung cancer. Participants will not need to visit a doctor or take new medicines for this study. Researchers will use information from existing medical records to answer the research question.

Status (registry)
Completed
Study type
Observational
Enrollment
21692 (actual)
First submitted
28 Dec 2025
Start date
Jan 2009
Primary completion date
Dec 2023
Lead sponsor
Samsung Medical Center
NCT number
NCT07332156

What you commit to

  • Study type: Observational
  • Participants enrolled: 21692
  • From Jan 2009 to the primary completion date, Dec 2023
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Concurrent prescribing of the study drugs at the index date
  • Exposure to the drugs of interest during the year preceding the index date

Other illness

  • Cancer
  • Death or cancer incidence within a month
    • In the sensitivity analysis, we are planning to substitute sulfonylurea to DPP4 inhibitors.

Other

  • Pre-existing
  • ESRD

Who the study is looking for

  • Adults aged ≥40 years with prior COPD (from 2009) and newly diagnosed diabetes who initiated SU or SGLT2i between January 1, 2014 and December 31, 2023

Age in the registry: 40 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.